Biofrontera

BFRI

Market cap $8.93M

Overview Fund Activity

0.8375 USD

-0.0037

0.44%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

0.8599

+0.0224

2.67%

1 day

-0.44%

5 days

0.9%

1 month

-9.95%

3 months

26.89%

6 months

-17.08%

Year to date

-23.17%

1 year

-33%

5 years

-99.05%

10 years

-99.05%

About: Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.

Employees: 93

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

23% more capital invested

Capital invested by funds: $1.18M [Q1] → $1.45M (+$269K) [Q2]

4.94% more ownership

Funds ownership: 16.69% [Q1] → 21.63% (+4.94%) [Q2]

8% less funds holding

Funds holding: 12 [Q1] → 11 (-1) [Q2]

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

See Fund Rankings

Financial journalist opinion

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

WOBURN, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced that the final patient in its Phase 2b clinical trial evaluating Ameluz® (aminolevulinic acid hydrochloride) for the treatment of moderate to severe acne vulgaris (AV) completed participation on August 22, 2025.

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Biofrontera Inc. (BFRI) Q2 2025 Earnings Conference Call Transcript

Biofrontera Inc. (NASDAQ:BFRI ) Q2 2025 Earnings Conference August 14, 2025 10:00 AM ET Company Participants Eugene Frederick Leffler - Chief Financial Officer Hermann Luebbert - CEO, President & Chairman Conference Call Participants Bruce David Jackson - The Benchmark Company, LLC, Research Division Jonathan Matthew Aschoff - ROTH Capital Partners, LLC, Research Division Andrew Barwicki - Unidentified Company Operator Good day, and welcome to the Biofrontera Inc. Second Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions] Please note that today's event is being recorded.

Biofrontera Inc. (BFRI) Q2 2025 Earnings Conference Call Transcript

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financial results for the three and six months ended June 30, 2025 and provided a business update.

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of George Jones as Chief Commercial Officer (CCO), starting August 25, 2025. In this role, Mr. Jones will oversee the Company's commercial functions, including sales, marketing, and market access. He will report directly to CEO Dr. Hermann Luebbert.

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2025 on Wednesday, August 13, 2025. The results will be released after the market close on Wednesday, August 13 and the company will host a conference call on Thursday, August 14 at 10:00am Eastern Time.

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment

Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz® and RhodoLED® including New Drug Application (NDA) and associated patents from Germany-based Biofrontera AG. Under their new agreement, the effective royalty rate paid by Biofrontera Inc. will be reduced to 12% (and 15% above revenue of $65 million) of net sales from 25% - 35% of net sales.

Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

WOBURN, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), confirms a disclosure by the Management Board of Biofrontera AG on June 10, 2025, according to which the two companies are in negotiations regarding a possible combination of the two companies or an adjustment of the license and supply agreement between them. The latter could result in the transfer of certain rights and obligations from Biofrontera AG to Biofrontera Inc. and a reduction in the transfer price for Biofrontera Inc.'s licensed products sold in the US.

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

WOBURN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the inclusion of the patent for its propylene glycol-free formulation of Ameluz® nanoemulsion gel in the US Food and Drug Administration's (FDA's) publication “Approved Drug Products with Therapeutic Equivalence Evaluations” (commonly known as the Orange Book).

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

Biofrontera Inc. (BFRI) Q1 2025 Earnings Call Transcript

Biofrontera Inc. (NASDAQ:BFRI ) Q1 2025 Earnings Conference Call May 16, 2025 10:00 AM ET Company Participants Andrew Barwicki - IR Representative Hermann Luebbert - CEO, Chairman, & Founder Fred Leffler - CFO Conference Call Participants Jonathan Aschoff - ROTH Capital Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Biofrontera's First Quarter 2025 Financial Results and Business Update Conference Call. All participants will be in listen-only mode.

Biofrontera Inc. (BFRI) Q1 2025 Earnings Call Transcript

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

Conference call begins at 10:00 a.m. Eastern time on Friday, May 16, 2025 WOBURN, Mass.

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

See News Rankings

Charts implemented using Lightweight Charts™